KARYOPHARM THERAPEUTICS Reports Q2 FY2023 Revenue of USD 37.6 Million, Down 5.3% from Previous Year

🌥️Earnings Overview

KARYOPHARM THERAPEUTICS ($NASDAQ:KPTI) reported total revenue of USD 37.6 million for the second quarter of FY2023, which ended on June 30 2023. This figure represents a 5.3% decrease from the same period in the previous year. The company also recorded a net income of USD -32.6 million, a notable improvement from the -49.1 million reported for the same quarter in 2023.

Analysis

GoodWhale has conducted an analysis of KARYOPHARM THERAPEUTICS‘s wellbeing, resulting in a low health score of 2/10. This suggests that the company is not well-positioned to ride out any potential economic crises without the risk of bankruptcy, due to its cashflows and debt levels. Furthermore, KARYOPHARM THERAPEUTICS is classified as a ‘rhino’, a type of company we conclude has achieved moderate revenue or earnings growth. Investors interested in KARYOPHARM THERAPEUTICS would likely be those focused on growth. The company is strong in terms of growth, medium in terms of asset, and weak in terms of dividend and profitability. As such, investors looking for long-term growth instead of quick returns may be more likely to invest in KARYOPHARM THERAPEUTICS. However, due to its low health score and potential financial instability, investors should conduct thorough research before investing in the company. More…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Karyopharm Therapeutics. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Karyopharm Therapeutics. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Karyopharm Therapeutics. More…

Key Ratios Snapshot

Some of the financial key ratios for Karyopharm Therapeutics are shown below. More…

Peers

The competition among Karyopharm Therapeutics Inc, Soleno Therapeutics Inc, Neovacs SA, and Shanghai Allist Pharmaceuticals Co Ltd is fierce. All four companies are vying for a share of the market for new cancer treatments. Karyopharm Therapeutics Inc has the most experience in developing new cancer treatments, but its competitors are quickly catching up. Soleno Therapeutics Inc has the most experience in clinical trials, but Neovacs SA has the most experience in manufacturing. Shanghai Allist Pharmaceuticals Co Ltd is the only company with experience in both developing new cancer treatments and manufacturing.

– Soleno Therapeutics Inc ($NASDAQ:SLNO)

Soleno Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare cardiovascular and metabolic diseases. The company’s lead product candidate is diazoxide choline controlled-release (DCCR), a once-daily oral tablet for the treatment of primary pulmonary hypertension (PPH) and other rare cardiovascular diseases. Soleno has completed a Phase 2 clinical trial of DCCR in patients with PPH and is currently enrolling patients in a Phase 3 clinical trial. The company also has a portfolio of other product candidates in various stages of development for the treatment of diabetes and other metabolic diseases.

– Neovacs SA ($LTS:0W8U)

Headquartered in Paris, France, Neovacs is a biopharmaceutical company focused on the development of active immunotherapies for the treatment of autoimmune and inflammatory diseases. The company’s lead product candidates are IFNalpha-Kinoid and TNF-Kinoid, which are in clinical development for the treatment of systemic lupus erythematosus and rheumatoid arthritis, respectively.

– Shanghai Allist Pharmaceuticals Co Ltd ($SHSE:688578)

Shanghai Allist Pharmaceuticals Co Ltd is a pharmaceutical company that manufactures and sells drugs in China. The company has a market cap of 10.29B as of 2022 and a Return on Equity of 2.58%. Allist is a leading manufacturer of drugs in China and has a strong presence in the domestic market. The company’s products are used in the treatment of various diseases and disorders, including cancer, cardiovascular disease, and diabetes. Allist has a strong research and development capability and has a number of new drugs in its pipeline. The company is well-positioned to benefit from the growing demand for pharmaceutical products in China.

Summary

KARYOPHARM THERAPEUTICS reported total revenue of USD 37.6 million for the second quarter of FY2023, representing a 5.3% decrease compared to the same period in 2023. This indicates that despite an overall decrease in revenue, KARYOPHARM THERAPEUTICS is making progress in reducing its net losses. Investors may note that the company is showing signs of improvement that may be worth considering when evaluating their stock performance.